SCHEMBL966435

SCHEMBL966435

CCCCNC(=O)NS(=O)(=O)CC(c1c(C)nn(C)c1-n1ccc2cc(Cl)ccc21)S(N)(=O)=O

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 6/20 0.33
CNR1 P21554 5/20 0.33
ALDH1A1 P00352 4/20 0.32
CYP2C9 P11712 2/20 0.32
HPGD P15428 2/20 0.32
CYP2C19 P33261 2/20 0.32
FBP1 P09467 1/20 0.32
TSHR P16473 3/20 0.32
LMNA P02545 2/20 0.32
PTGDR Q13258 1/20 0.32
PTGDR2 Q9Y5Y4 1/20 0.32
ALB P02768 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
MAPK8 P45983 1/20 0.32
AGTR2 P50052 2/20 0.32
KDM4E B2RXH2 1/20 0.31
HSD17B10 Q99714 1/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
CYP3A4 P08684 1/20 0.31
THRB P10828 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL964880 0.82 TP53 (0.37) CNR2CNR1ALDH1A1CYP2C9HPGD
SCHEMBL964783 0.82 HTR2A (0.35) MAPK8HTR2APHGDHNPY5R
SCHEMBL964870 0.80 PPARG (0.38) CNR2CNR1MAPK8PPARG
SCHEMBL966437 0.79 CNR2 (0.35) CNR2CNR1ALDH1A1CYP2C9HPGD
SCHEMBL966434 0.79 CNR2 (0.35) CNR2CNR1ALDH1A1CYP2C9HPGD
SCHEMBL963042 0.78 TP53 (0.40) CNR2CNR1MAPK8PPARG
SCHEMBL4554288 0.77 TP53 (0.38) CNR2CNR1ALDH1A1CYP2C19TSHR
SCHEMBL962603 0.76 RAB9A (0.39) ALDH1A1TDP1KDM4ESMN1; SMN2THRB
SCHEMBL963019 0.76 TP53 (0.37) CNR2CNR1ALDH1A1CYP2C9HPGD
SCHEMBL968528 0.75 CDC7 (0.35) MAPK8NPY5R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110009384-A1 FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA TAKEDA PHARMACEUTICAL COMPANY LIMITED 2011-01-13 US disclosed
EP-2118066-A1 FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA Takeda Pharmaceutical Company Limited (JP) 2009-11-18 EP disclosed
WO-2008099794-A1 FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-08-21 WO disclosed
US-20080194617-A1 Fused ring compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194617-A1 Fused ring compound SLC5A1, SLC5A2, GPR119 CNR2 2360/4885CNR1 1414/4885ALDH1A1 421/4885
US-20110009384-A1 FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA PPARA, PPARD, PPARG CNR2 290/4885CNR1 153/4885ALDH1A1 821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.